Gut Microbe Streptococcus mutans Fuels Parkinson's Disease via Brain-Reaching Metabolite

Parkinson's disease (PD) is the world's second most common neurodegenerative disorder, marked by the selective death of midbrain dopaminergic neurons and aggregation of α-synuclein protein. While genetic mutations account for some cases, the majority are idiopathic, pointing to environmental contributors. The gut microbiome has long been suspected as a key environmental mediator, but the specific microorganisms and metabolites causally driving PD pathology have remained elusive — until now.

This study began with a reanalysis of a large publicly available whole-genome shotgun sequencing dataset from 491 PD patients and 234 healthy controls. The investigators confirmed that Streptococcus mutans — an oral bacterium — was among the most significantly enriched species in the gut microbiome of PD patients. Crucially, the gene urdA, encoding urocanate reductase (UrdA), the enzyme S. mutans uses to convert urocanate into imidazole propionate (ImP), was significantly elevated in PD patients' gut microbiomes. ImP plasma levels were also measurably higher in PD patients compared to healthy controls, providing a direct human correlate.

To establish causality, the team colonized germ-free mice with live S. mutans, pasteurized (killed) S. mutans, or vehicle. Only live S. mutans colonized the gut and elevated plasma and brain ImP levels. These mice developed hallmark PD features: loss of tyrosine hydroxylase (TH)-positive dopaminergic neurons in the substantia nigra pars compacta (SNpc), reactive astrogliosis, microgliosis, and motor impairment on the pole test. Pasteurized S. mutans produced none of these effects. Additionally, colonization with an E. coli strain engineered to express UrdA from S. mutans replicated the PD-like pathology, and S. mutans further exacerbated α-synuclein pathology in an existing PD mouse model. Critically, direct ImP administration alone was sufficient to reproduce the core PD pathological features, confirming ImP as the active mediator.

Mechanistically, the study found that mTORC1 activation is essential for both S. mutans- and ImP-induced PD pathology. Inhibiting mTORC1 signaling attenuated the neurodegeneration and neuroinflammation observed, identifying this pathway as a druggable target downstream of gut-derived ImP. This positions the UrdA–ImP–mTORC1 axis as a mechanistically coherent, microbiome-driven pathway in PD.

These findings are significant because they identify a specific bacterium, a specific enzyme, and a specific brain-permeable metabolite that collectively constitute a causal chain from the gut to the brain in PD. The work provides a strong rationale for targeting S. mutans abundance, UrdA enzyme activity, or ImP levels as novel therapeutic strategies. Caveats include the use of germ-free mouse models, which lack a full commensal microbiome and may not fully replicate human PD complexity, and that human data remain correlational.